ASCO-Update 2015 – Neuigkeiten vom 51. Meeting der American Society of Clinical Oncology/ASCO 2015

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Zeitschrift für Gastroenterologie - German Journal of Gastroenterology

• Publication date

  2004-12-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1055/s-0041-111632PMID 26854837
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma: Analysis of REACH Trial Results by Child-Pugh Score

  2017cited by this paper
• PD-1 blockade in tumors with mismatch repair deficiency.

  2015cited by this paper
• PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

  2015cited by this paper
• Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040.

  2015cited by this paper
• Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial.

  2015cited by this paper
• Cochrane systematic review and meta-analysis of adjuvant therapy for stage II colon cancer.

  2015cited by this paper
• Relationship between PD-L1 expression and clinical outcomes in patients (Pts) with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (Pembro; MK-3475) in KEYNOTE-012.

  2015cited by this paper
• Lanreotide depot/autogel (LAN) in patients with neuroendocrine tumors (NETs) aged 65 years: Subgroup analyses from the CLARINET study.

  2015cited by this paper
• Neoadjuvant chemotherapy for resectable oesophageal and junctional adenocarcinoma: Results from the UK Medical Research Council randomised OEO5 trial (ISRCTN 01852072).

  2015cited by this paper
• INTEGRATE: A randomized, phase II, double-blind, placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC): A study by the Australasian Gastrointestinal Trials Group (AGITG)—Final overall and subgroup results.

  2015cited by this paper
• METGastric: A phase III study of onartuzumab plus mFOLFOX6 in patients with metastatic HER2-negative (HER2-) and MET-positive (MET+) adenocarcinoma of the stomach or gastroesophageal junction (GEC).

  2015cited by this paper
• Prognostic value of BRAF V600E and KRAS exon 2 mutations in microsatellite stable (MSS), stage III colon cancers (CC) from patients (pts) treated with adjuvant FOLFOX+/- cetuximab: A pooled analysis of 3934 pts from the PETACC8 and N0147 trials.

  2015cited by this paper
• Toxicity and quality of life data from SCOT: An international phase III randomized (1:1) noninferiority trial comparing 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy.

  2015cited by this paper
• Phase Ib study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated metastatic colorectal cancer and advanced cancers.

  2015cited by this paper
• Comprehensive molecular characterization of colorectal cancer reveals genomic predictors of immune cell infiltrates.

  2015cited by this paper
• SIRFLOX: Randomized phase III trial comparing first-line mFOLFOX6 {+/-} bevacizumab (bev) versus mFOLFOX6 + selective internal radiation therapy (SIRT) {+/-} bev in patients (pts) with metastatic colorectal cancer (mCRC).

  2015cited by this paper
• High response rate and PFS with PEGPH20 added to nab-paclitaxel/gemcitabine in stage IV previously untreated pancreatic cancer patients with high-HA tumors: Interim results of a randomized phase II study.

  2015cited by this paper
• Panitumumab in combination with gemcitabine/cisplatin (GemCis) for patients with advanced kRAS WT biliary tract cancer: A randomized phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

  2015cited by this paper
• Analysis of DNA mismatch repair (MMR) and clinical outcome in stage III colon cancers from patients (pts) treated with adjuvant FOLFOX +/- cetuximab in the PETACC8 and NCCTG N0147 adjuvant trials.

  2015cited by this paper
• CONKO-005: Adjuvant therapy in R0 resected pancreatic cancer patients with gemcitabine plus erlotinib versus gemcitabine for 24 weeks—A prospective randomized phase III study.

  2015cited by this paper
• Everolimus in patients with advanced, progressive pancreatic neuroendocrine tumors: Overall survival results from the phase III RADIANT-3 study after adjusting for crossover bias.

  2015cited by this paper
• Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E+B) in patients (Pts) with locally advanced or metastatic pancreatic neuroendocrine tumors (pNET), CALGB 80701 (Alliance).

  2015cited by this paper
• Multicenter prospective phase II trial of bevacizumab (bev) for progressive pancreatic neuroendocrine tumor (PNET).

  2015cited by this paper
• HER-FLOT: Trastuzumab in combination with FLOT as perioperative treatment for patients with HER2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the AIO Gastric Cancer Study Group.

  2014cited by this paper
• Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy.

  2013cited by this paper
• Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5‐fluorouracil, oxaliplatin and docetaxel

  2012cited by this paper

• Gastroösophageale Refluxkrankheit

  2019cites this paper
• Helicobacter pylori Eradication Therapy for Functional Dyspepsia: A Meta-Analysis by Region and H. pylori Prevalence

  2019cites this paper
• Perioperative Therapy of Oesophagogastric Adenocarcinoma: Mainstay and Future Directions

  2017cites this paper